GSK
GSK plc$50.74
-2.16%LiveJun 22, 2026
Market cap
$101.68B
52w range
35.45 – 61.70
P / E
—
EPS
—
Volume
3.48M
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on GSK plc’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $52.45 (+3.37%)
Candlestick · 1Y
Open in chart workstation →GSK
50.67+32.44%H 61.70L 35.45MA50 52.66MA200 50.08Avg vol 4.8M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.14% | -3.32% | -1.25% | -2.12% | +4.42% | +3.47% | +32.62% | +46.31% | +29.84% | +21.50% | +7631.81% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$50.67
Bid
$50.55
400 sh
Ask
$60.46
600 sh
Spread
$9.910
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewilderingseekingalpha.com·Jun 18, 2026
- GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infectionszacks.com·Jun 18, 2026
- US FDA approves GSK's oral antibiotic for drug-resistant UTIsreuters.com·Jun 17, 2026
- GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorderzacks.com·Jun 12, 2026
- Is GSK PLC (GSK) Overvalued After 3.3% Rally? GF Value Says Overvaluedgurufocus.com·Jun 11, 2026
- Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billionmarketbeat.com·Jun 11, 2026
- Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent dealreuters.com·Jun 11, 2026
- GSK plc (GSK) M&A Call Transcriptseekingalpha.com·Jun 10, 2026
Recent analyst activity
DB- Jun 09, 2026GradeOutperform → OutperformRBC Capital: 'On balance we think readthroughs from the GSK acquisition of NUVB's key competitor are positive'RBC Capital
Financial scores
DBJun 19, 2026Altman Z
1.67
Distress
≥ 3.0 safe · 1.81–3.0 grey · < 1.81 distress
Piotroski F
7/9
Strong
≥ 7 strong · 4–6 average · < 4 weak
Peers
No peer list available for GSK.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|